54 results on '"Bacher, U."'
Search Results
2. Impact of molecular residual disease post allografting in myelofibrosis patients
3. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
4. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
5. Stammzelltransplantation bei malignen Lymphomen
6. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor
7. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups
8. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome
9. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
10. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
11. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
12. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics
13. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations
14. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
15. Landmark analysis of DNMT3A mutations in hematological malignancies
16. Donor choice according to age for allo-SCT for AML in complete remission
17. Moderne Diagnostik bei akuten und chronischen Leukämien
18. Diagnostik akuter Leukämien
19. Evaluation of BM cytomorphology after allo-SCT in patients with MDS
20. Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma
21. Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia
22. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
23. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype
24. Evaluation of BM cytomorphology after allo-SCT in patients with AML
25. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
26. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia
27. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics
28. Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT
29. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
30. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms
31. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT
32. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment
33. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
34. Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors
35. Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity
36. Interactive diagnostics in the indication to allogeneic SCT in AML
37. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features
38. Gene expression analyses in acute myeloid leukaemia (AML): current status and perspectives
39. Outcome of allo-SCT for chronic myelomonocytic leukemia
40. Erratum: Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
41. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
42. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT
43. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
44. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques
45. A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment
46. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis
47. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases
48. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients
49. Gene expression profiling for the diagnosis of acute leukaemia
50. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.